LETROZOLEXIN 2.5 BLISTER - Euro-Pharmacies

Released as Femara in 1997, letrozole quickly earned a top place in breast cancer treatment for its superior estrogen-lowering capacity. Originally meant as a secondary treatment after tamoxifen, its strength allowed it to suppress estrogen up to 78%. With substantial effects even at minimal dosages, letrozole also found a role in athletics for those managing estrogen-related side effects. Available in most nations, Femara’s effectiveness continues to be highly respected, but monitoring is recommended due to possible joint discomfort and lowered HDL levels​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about LETROZOLEXIN 2.5 BLISTER by Euro-Pharmacies, consult with your doctor or healthcare professional.